A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease
Conclusions: Results of this trial will provide important information on the feasibility, safety, and tolerability of long-term use of metformin in patients with ADPKD and provide preliminary information regarding its efficacy in slowing disease progression. Furthermore, results may support or refute the hypothesis that metformin effects on disease progression are mediated through the activation of the AMPK pathway. These results will be essential for the justification and design of a full-scale efficacy trial.Am J Nephrol 2018;47:352 –360
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Clinical Trials | Cystic Fibrosis | Fortamet | Gastroenterology | Liver | Metformin | Neurology | Pain | Polycystic Kidney Disease | Study | Urology & Nephrology